Market Cap ₹2314 Cr.
Stock P/E 42.0
P/B 3.8
Current Price ₹435
Book Value ₹ 113
Face Value 2
52W High ₹646.4
Dividend Yield 0%
52W Low ₹ 390.5
Tarsons Products Ltd, a life sciences enterprise, engages in designing, growing, production, and advertising consumables, reusables, and others for use in numerous laboratories in India. The corporation provides consumables, consisting of centrifuge ware, cryogenic ware, liquid handling, PCR consumables and petri dish, switch pipettes, and others; reusables, along with bottles, carboys, beakers, measuring cylinders, and tube racks; and benchtop instrumentation, which includes vortex shakers, centrifuges pipettors, and others. It serves studies groups, academia institutes, pharmaceutical groups, contract research businesses, diagnostic organizations, and hospitals via legal vendors. The agency also exports its products to Europe, Africa, North America, Australia, and Asia. Tarsons Products Ltd founded in 1983 and is situated in Kolkata, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Sep 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|---|---|
Net Sales | 76 | 69 | 71 | 61 | 82 | 63 | 66 |
Other Income | 1 | 3 | 4 | 3 | 2 | 2 | 3 |
Total Income | 77 | 71 | 75 | 65 | 84 | 65 | 69 |
Total Expenditure | 38 | 37 | 39 | 35 | 43 | 41 | 41 |
Operating Profit | 40 | 34 | 36 | 30 | 41 | 24 | 28 |
Interest | 2 | 0 | 1 | 1 | 2 | 2 | 1 |
Depreciation | 5 | 6 | 7 | 7 | 8 | 8 | 10 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 34 | 27 | 29 | 22 | 31 | 13 | 17 |
Provision for Tax | 9 | 7 | 7 | 5 | 8 | 3 | 5 |
Profit After Tax | 25 | 20 | 21 | 16 | 23 | 10 | 13 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 25 | 20 | 21 | 16 | 23 | 10 | 13 |
Adjusted Earnings Per Share | 4.9 | 3.8 | 4 | 3 | 4.3 | 1.8 | 2.4 |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|---|---|
Net Sales | 179 | 176 | 229 | 301 | 283 | 272 |
Other Income | 6 | 5 | 6 | 8 | 12 | 10 |
Total Income | 185 | 181 | 234 | 309 | 296 | 283 |
Total Expenditure | 107 | 108 | 126 | 148 | 154 | 160 |
Operating Profit | 78 | 73 | 109 | 161 | 142 | 123 |
Interest | 7 | 6 | 3 | 4 | 4 | 6 |
Depreciation | 15 | 14 | 14 | 22 | 29 | 33 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
Profit Before Tax | 56 | 53 | 92 | 135 | 109 | 83 |
Provision for Tax | 17 | 13 | 24 | 34 | 28 | 21 |
Profit After Tax | 39 | 41 | 69 | 101 | 81 | 62 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 39 | 41 | 69 | 101 | 81 | 62 |
Adjusted Earnings Per Share | 7.7 | 7.6 | 13.5 | 18.9 | 15.2 | 11.5 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | -6% | 17% | 0% | 0% |
Operating Profit CAGR | -12% | 25% | 0% | 0% |
PAT CAGR | -20% | 25% | 0% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | -22% | NA% | NA% | NA% |
ROE Average | 15% | 25% | 25% | 25% |
ROCE Average | 19% | 31% | 30% | 30% |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Shareholder's Funds | 135 | 198 | 244 | 490 | 569 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 |
Borrowings | 19 | 6 | 3 | 9 | 81 |
Other Non-Current Liabilities | 4 | 77 | 102 | 139 | 142 |
Total Current Liabilities | 113 | 40 | 42 | 35 | 88 |
Total Liabilities | 271 | 321 | 392 | 673 | 879 |
Fixed Assets | 89 | 92 | 120 | 189 | 225 |
Other Non-Current Assets | 26 | 109 | 159 | 240 | 378 |
Total Current Assets | 156 | 120 | 113 | 245 | 277 |
Total Assets | 271 | 321 | 392 | 673 | 879 |
#(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 1 | 1 | 25 | 2 | 77 |
Cash Flow from Operating Activities | 51 | 64 | 68 | 83 | 76 |
Cash Flow from Investing Activities | -34 | -25 | -64 | -138 | -179 |
Cash Flow from Financing Activities | -18 | -14 | -27 | 130 | 85 |
Net Cash Inflow / Outflow | -0 | 25 | -23 | 75 | -18 |
Closing Cash & Cash Equivalent | 1 | 25 | 2 | 77 | 59 |
# | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|---|---|
Earnings Per Share (Rs) | 7.66 | 7.65 | 13.54 | 18.92 | 15.17 |
CEPS(Rs) | 10.52 | 10.32 | 16.22 | 23.05 | 20.53 |
DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
Book NAV/Share(Rs) | 26.59 | 37.28 | 48.02 | 92.06 | 107 |
Core EBITDA Margin(%) | 40.06 | 38.88 | 45.11 | 50.77 | 45.66 |
EBIT Margin(%) | 35.29 | 33.68 | 41.57 | 46.28 | 39.96 |
Pre Tax Margin(%) | 31.23 | 30.21 | 40.38 | 44.88 | 38.38 |
PAT Margin (%) | 21.79 | 23.04 | 30.09 | 33.47 | 28.5 |
Cash Profit Margin (%) | 29.94 | 31.1 | 36.05 | 40.77 | 38.56 |
ROA(%) | 14.38 | 13.69 | 19.32 | 18.9 | 10.4 |
ROE(%) | 28.8 | 24.35 | 31.17 | 27.42 | 15.24 |
ROCE(%) | 31.57 | 27.35 | 37.22 | 35.28 | 19 |
Receivable days | 91.05 | 85.89 | 67.95 | 68.08 | 84.39 |
Inventory Days | 94.84 | 98.74 | 76.08 | 78.31 | 126.77 |
Payable days | 14.45 | 29.71 | 35.25 | 54.91 | 63.4 |
PER(x) | 0 | 0 | 0 | 37.22 | 35.12 |
Price/Book(x) | 0 | 0 | 0 | 7.65 | 4.98 |
Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
EV/Net Sales(x) | 0.36 | 0.06 | 0.13 | 12.24 | 10.19 |
EV/Core EBITDA(x) | 0.82 | 0.13 | 0.28 | 22.85 | 20.36 |
Net Sales Growth(%) | 0 | -1.59 | 30.14 | 31.4 | -5.83 |
EBIT Growth(%) | 0 | -6.08 | 60.64 | 46.29 | -18.69 |
PAT Growth(%) | 0 | 4.04 | 69.92 | 46.17 | -19.82 |
EPS Growth(%) | 0 | -0.12 | 77 | 39.78 | -19.82 |
Debt/Equity(x) | 0.48 | 0.18 | 0.14 | 0.04 | 0.19 |
Current Ratio(x) | 1.38 | 2.96 | 2.7 | 7 | 3.16 |
Quick Ratio(x) | 0.97 | 1.76 | 1.58 | 4.64 | 1.85 |
Interest Cover(x) | 8.7 | 9.71 | 34.96 | 33.02 | 25.34 |
Total Debt/Mcap(x) | 0 | 0 | 0 | 0.01 | 0.04 |
# | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 47.3 | 47.31 | 47.31 | 47.31 | 47.31 | 47.31 | 47.31 | 47.31 | 47.31 | 47.31 |
FII | 9.33 | 9.12 | 9.33 | 9.89 | 9.59 | 9.15 | 8.64 | 7.85 | 6.83 | 8.16 |
DII | 6.33 | 7.76 | 8.06 | 8.13 | 8.52 | 8.45 | 7.38 | 3.16 | 2.6 | 0.17 |
Public | 37.04 | 35.82 | 35.31 | 34.68 | 34.58 | 35.09 | 36.67 | 41.69 | 43.27 | 44.36 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 |
FII | 0.5 | 0.49 | 0.5 | 0.53 | 0.51 | 0.49 | 0.46 | 0.42 | 0.36 | 0.43 |
DII | 0.34 | 0.41 | 0.43 | 0.43 | 0.45 | 0.45 | 0.39 | 0.17 | 0.14 | 0.01 |
Public | 1.97 | 1.91 | 1.88 | 1.84 | 1.84 | 1.87 | 1.95 | 2.22 | 2.3 | 2.36 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About